Iteos Therapeutics Inc
NASDAQ:ITOS

Watchlist Manager
Iteos Therapeutics Inc Logo
Iteos Therapeutics Inc
NASDAQ:ITOS
Watchlist
Price: 10.15 USD Market Closed
Market Cap: 448.7m USD

During the last 3 months Iteos Therapeutics Inc insiders have not bought any shares, and have not sold any shares.

The last transaction was made on Jun 10, 2025 by Detheux Michel , who sold 84.2k USD worth of ITOS shares.

Last Transactions:
Detheux Michel
$-84.2k
Detheux Michel
$-84.3k
Detheux Michel
$-85.8k
Hallal David
$-391.5k
Detheux Michel
$-85.3k
Hallal David
$-388k
Detheux Michel
$-84.8k
Hallal David
$-384.9k
Ecor1 Capital, Llc
$+26.4m
Ecor1 Capital, Llc
$+12.3m
Mpm Bioventures 2018, L.p.
$-5.1m
Evnin Luke
$-5.1m
Gadicke Ansbert
$-8.3m
Gall Matthew
$+38.6k
Ra Capital Healthcare Fund Lp
$+100m
Gall Matthew
$+41.9k
Lewis Joseph
$-494.5k
Hallal David
$-22.8k
Hallal David
$-121.7k
Davis Aaron I.
$-15.6k
Davis Aaron I.
$-2.4m
Davis Aaron I.
$-572.7k
Davis Aaron I.
$-196.4k
Davis Aaron I.
$-282.2k
Davis Aaron I.
$-4.1m
Detheux Michel
$-365.5k
Davis Aaron I.
$+657k
Davis Aaron I.
$+678.9k
Detheux Michel
$-194.7k
Lewis Joseph
$-20.3m
Lager Joanne Jenkins
$-126k
Mcgrath Yvonne
$-367.6k
View All Transactions

During the last 3 months Iteos Therapeutics Inc insiders have not bought any shares, and have not sold any shares.

The last transaction was made on Jun 10, 2025 by Detheux Michel , who sold 84.2k USD worth of ITOS shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
20.1m USD
5
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
1
38.7m USD
9-12
months
No Insider Transactions
0
0 USD

Iteos Therapeutics Inc
Insider Trading Chart

Iteos Therapeutics Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Iteos Therapeutics Inc
Last Insider Transactions

Global
Insiders Monitor

Iteos Therapeutics Inc
Glance View

Market Cap
448.7m USD
Industry
Biotechnology

iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. The company is headquartered in Watertown, Massachusetts and currently employs 94 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery and development of differentiated immuno-oncology therapeutics for patients. The firm's pipeline includes two clinical-stage programs: EOS-448 and Inupadenant (EOS-850). The Company’s lead antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), an immune checkpoint with multiple mechanisms of action, which leads to immunosuppression. Its EOS-850, is designed as a selective small molecule antagonist of the adenosine A2a receptor (A2AR) in the adenosine triphosphate (ATP) adenosine pathway. The firm is conducting an open-label multi-arm Phase I/II clinical trial of inupadenant in adult cancer patients with advanced solid tumors.

ITOS Intrinsic Value
0.46 USD
Overvaluation 95%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top